Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

Low-density lipoprotein, known as LDL, is a complex structure with several components that allow cholesterol to circulate in ...

Table 1. Target levels or percentage decreases of total cholesterol, LDL cholesterol and lipoprotein(a) to be achieved by lipoprotein apheresis. Baseline refers to levels immediately ...

Lipoprotein(a) is a type of cholesterol that lurks in the body, undetected by routine tests and undeterred by existing drugs, diet or exercise. The findings, cardiologists say, are a critical step ...

Authors say findings call for primary prevention strategies to extend beyond traditional 10-year estimates. HealthDay News — A single combined measure of high-sensitivity C-reactive protein (CRP ...

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein(a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the ...

The FDA cleared a new lipoprotein assay designed to measure lipoprotein(a) in nmol/L. Measuring nmol/L rather than mg/dL may improve diagnostic accuracy during CV risk assessment. Roche announced ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. CHICAGO — Lipoprotein(a) is a risk factor for cardiovascular disease you may not ...

Lipoprotein apheresis involves the extracorporeal removal of LDL and lipoprotein(a) particles from whole blood or plasma by adsorption, precipitation or differential filtration. Used repetitively ...

The study data support efforts to extend strategies for the primary prevention of atherosclerotic events beyond traditional 10-year estimates of risk. HealthDay News — A single combined measure ...